Jonathan Gluck Was Told His Cancer Was a Death Sentence. 22 Years Later, He Shares How Science Saved Him (Exclusive)
In 2003, writer and editor Jonathan Gluck was diagnosed with an incurable blood cancer
He was 38 — and a new dad — and told he had less than three years to live
Advancements in cancer treatments have kept him alive for more than two decades, he writes in his new memoir, An Exercise in Uncertainty: A Memoir of Illness and Hope In April, when Jonathan Gluck turned 60, friends urged him to mark the milestone with a blowout event. After all, 'no one was sure I'd reach 60,' he says. But the writer and former managing editor of Vogue magazine wasn't interested: 'I was like, 'I don't want to tempt the fates.' '
After being diagnosed with multiple myeloma, an incurable blood cancer that develops in the bone marrow and damages bones and the immune system, at the age of 38, Gluck knows he's already outlived his predicted expiry date by 20 years. But the truth is, he did want to celebrate, in his own quiet way.
So, he, his wife, Didi, and their 17-year-old son flew from their New York City home to Ohio to visit their daughter at college — and they had a birthday dinner in the school cafeteria. On the menu: a 'throwback to the '70s' salad bar and chocolate chip pretzel cookies. 'I couldn't have been happier,' he says. 'It was about being together, the four of us.'
Finding joy in the day-to-day has been one of the 'strange gifts' of Gluck's life with cancer. 'It comes naturally,' says the writer, whose new memoir An Exercise in Uncertainty: A Memoir of Illness and Hope chronicles how he learned to accept living with an incurable disease and examines the remarkable developments in cancer treatment that have kept him alive.
'When you receive a serious diagnosis, you're forced to think about death a lot more than most people, which is awful in a lot of ways,' he says. 'But there's a sense of urgency to everything for me that I think is useful to anyone. It inspired me to make the most of my time, whether that's with my kids, my career, my friends, or my marriage."
In 2003, Gluck was a rising star in the New York publishing world, and he felt like he had it all. A veteran of Men's Health, He'd just been hired as deputy editor of New York magazine—and better still, he and his wife, fellow journalist Didi Gluck, had welcomed their first child, a daughter named Abigail Juliana.
When A.J., as they called her, was seven months old, Gluck went to a doctor about a stabbing pain in his hip that had been bothering him for a year after falling on a patch of ice. Worst case, he figured, he'd need hip surgery. But his MRI results delivered a more shocking blow: cancer. After a battery of tests, he learned he was facing multiple myeloma, a blood cancer with recurring tumors that eat away at bone marrow, and which at the time carried a life expectancy of less than three years. Gluck was told he might not survive more than 18 months. 'The minute I heard the news, it was like, game over,' Gluck recalls.
He started radiation, had his stem cells harvested — and was elated when he went into remission. But then he began a now-familiar wait for the next sign of trouble. 'Living with an incurable disease is like sleeping next to a hibernating bear,' Gluck writes. 'For the moment, I felt safe, but I knew it was only a matter of time before the bear woke up.'
Distraction became a refuge: He threw himself into work, and over the years has discovered Zen-like healing in fly-fishing. 'Your mind tends to not go to all the scary, dark places,' says Gluck of the meditative rhythm of casting a line, which he's been known to practice on his NYC neighborhood street.
With an infant at home, he also poured himself into parenting. 'My single greatest fear was, 'Am I going to miss out on being a dad?'' he says. 'Time with A.J. helped not only keep my mind off of bad things, but put my mind on good things.'
Just before Gluck hit his three-year mark in remission, he and Didi decided to try for a second child. "My wife has been extremely optimistic throughout this whole process and that was one of the most optimistic moments in her," Gluck says, "She helped lead us through, because she didn't hesitate for a split second. She was like, 'It's going to be okay one way or the other. We're having a second kid.' "
But in 2007, four months before their son Oscar was born, Gluck cracked a rib while turning around in his chair at work. Another tumor. Another cycle of radiation, just as he and Didi, now 54, were preparing for their son. Two years later, scans revealed more lesions. From that point forward, it was as if his doctors were playing 'whack-a-mole,' Gluck writes.
The relentless strain of illness, caregiving, and the looming possibility of death, took a toll on Gluck's marriage, which by 2013 was nearing a breaking point, culminating in a screaming match on the streets of the East Village. ('We were the couple other people tried not to stare at,' he writes with painful honesty of the fight.) 'It was like we were preparing ourselves for when I was gone,' says Gluck. 'It's difficult to love somebody when you're afraid they might disappear tomorrow. And it's difficult to love somebody when you have tremendous guilt that you're not going to be here for her or our kids.'
Therapy helped them find their way back: 'We started to rebuild. We forgave each other.' And they accepted the reality of their dynamic. As Didi once said to him, 'No marriage doesn't have a 'thing'... Cancer is our thing.'
Gluck knows there's an odd 'right time/right place' aspect to his cancer. New targeted therapies were developed just as his disease progressed. Some have come with harsh side effects — notably, he writes, uncontrollable diarrhea that caused him to lose 25 pounds and at times saw him dashing from Vogue meetings to the restroom. Other treatments, like CAR T-cell therapy, which genetically modifies a patient's cells to fight cancer, have left his immune system vulnerable.
'I'm slowly getting better, but I'm still living like we all were in the pandemic. I wear a mask in any crowded indoor place. I avoid super crowded places best I can.' But they've bought him precious time. 'Sometimes I walk down the street and shake my head and think, 'How have I survived this?'' he says. "It's not a stretch to say I'm a medical miracle."
Nearly two years after his "mind-blowingly futuristic" CAR-T therapy, which he says left him feeling "reborn," Gluck says 'cancer-wise, I'm doing great.' He marvels over the scientific breakthroughs that have saved him each time his cancer returned. At the same time, he's prone to knocking on wood and kissing his knuckles for good measure. 'I've become quite superstitious,' he admits.
The disease and treatments have left their marks, however: numbness in his fingers and toes, gastrointestinal problems and bone pain in his hips, spine and neck. He takes six pills, a powder and two liquid medicines daily. And every two months for the rest of his life he needs to get an immunoglobulin infusion to keep his immune system functioning— a procedure that can take up to five hours.
It's a small price to pay, he says: 'The moment I was diagnosed, I tried to make a deal with God — 'Just let me see A.J.'s high school graduation.' In my wildest imagination, I didn't think it would happen.' But, as he says, "What better motivation do any of us have than staying alive for our kids?"
Last month, he saw A.J. earn her college degree. Next year, his son Oscar will graduate from high school. 'When you're told you might have as little as a year and a half to live and you wind up seeing all these wonderful milestones, you know you're pretty lucky.'Twenty years ago, when Gluck was diagnosed with multiple myeloma, the disease 'was a death sentence,' says Dr. Hearn Jay Cho, chief medical officer with the Multiple Myeloma Research Foundation who is also a clinical professor of medicine at the Icahn School of Medicine at Mt. Sinai and an attending physician with the Multiple Myeloma Service at the Mt. Sinai Tisch Cancer Institute. 'We'd tell people to get their affairs in order because it was bad.'Life expectancy was two to three years. Today, there are 36,000 new cases of myeloma in the U.S., annually, and median survival is about 10 years, with many patients dying of something other than the disease. 'We've made incredible progress,' says Cho.The drugs Revlimid and Velcade, introduced in 2006-2007, were 'game changers,' he says. 'Before, only about a third of patients had any response to conventional chemotherapy.' With those drugs, 60% to 80% of patients responded, and 'about a third would go into complete remission.' Stem cell transplant therapy and targeted monoclonal antibody drugs like Daratumumab further improved outcomes. Then, in 2021, the FDA first approved CAR T-cell therapy for myeloma, shown to be effective for patients, like Gluck, who'd relapsed after standard therapies.'You can keep patients alive and with good quality of life for a long time,' says Cho, who points out that's due to vital investment in science. 'The job's not done, and we need to finish it. A lot of people are working hard to come up with a cure. Someone like Jon Gluck is alive and kicking today because of medical research.'Read the original article on People
Hashtags

Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles


Medscape
6 hours ago
- Medscape
MRI-Led Surveillance Stratifies Prostate Cancer Risk
In a cohort study of patients with prostate cancer, MRI-led risk-adapted active surveillance demonstrated effectiveness in risk stratification. The approach showed that MRI visibility and the presence of secondary Gleason pattern 4 at baseline were associated with higher rates of progression and treatment initiation. METHODOLOGY: Researchers analysed 1150 patients who started active surveillance between February 2000 and July 2023, including those with a Gleason score (GS) ≤ 3 + 4, prostate-specific antigen (PSA) < 20 ng/mL, and at least two MRI scans. Participants underwent PSA testing three to four times in the first year, followed by biannual testing; MRI was performed at baseline and 12 months, with an additional MRI scan performed at 24 months for those with MRI-visible lesions at baseline. Patients were stratified into four groups on the basis of baseline risk factors, including GS (3 + 3 vs 3 + 4) and MRI visibility ("non-visible disease" vs "visible disease"). The primary outcome was event-free survival, with an event defined as the detection of GS ≥ 4 + 3 or the initiation of any prostate cancer treatment. The median follow-up duration was 64 months per person overall and 72 months for 732 patients without an event. At baseline, 64% of patients had GS 3 + 3 and 36% had GS 3 + 4; 49% of those with GS 3 + 4 had MRI-visible disease. TAKEAWAY: Event-free survival rates varied significantly on the basis of the risk group, with 5-year rates of 91% for non-visible GS 3 + 3, 71% for MRI-visible GS 3 + 3, 71% for non-visible GS 3 + 4, and 44% for MRI-visible GS 3 + 4 disease. Among 487 patients who underwent follow-up biopsies, histological upgrade to GS ≥ 4 + 3 occurred in 67 patients; non-visible GS 3 + 3 cases had 5- and 10-year rates of 1.2% and 6.1%, respectively, for histological progression to GS ≥ 4 + 3, while the rates were 17% and 43% for those with MRI-visible GS 3 + 4 disease at baseline, respectively. Progression to nodal or bone metastases was observed in 10 patients, occurring only in those who had declined recommended follow-up MRI and/or biopsies. The 10-year rate of commencing treatment was 28% for those with non-visible GS 3 + 3 disease vs 85% for those with MRI-visible GS 3 + 4 disease and 46% for those with non-visible GS 3 + 4 disease vs 54% for those with MRI-visible GS 3 + 3 disease. IN PRACTICE: "Results from our cohort suggest that AS [active surveillance] patients can be monitored safely with MRI, and the decision to biopsy was based on MRI findings and PSA changes. Prospective, multicentre, clinical trials are required and currently being designed to further evaluate this approach," the authors wrote. SOURCE: This study was led by Cameron Englman, Division of Surgery & Interventional Science, University College London, London, England. It was published online on May 27, 2025, in European Urology . LIMITATIONS: Compared with time-based biopsy protocols, the MRI-led risk-adapted approach may underestimate histological progression. Additionally, as a cohort study without a strict protocol, practice evolved alongside contemporary pathology and radiology standards, with MRI quality, reporting standards, and the definition of radiological progression varying over time, particularly improving after the adoption of the PRECISE recommendations in 2016. DISCLOSURES: This study did not receive any specific funding. Several authors reported receiving consulting fees and grants and having other ties with various sources.


Medscape
7 hours ago
- Medscape
Radiology Workforce Shortages Impacting Cancer Care
A chronic shortage of radiologists and oncologists is putting patients in the UK at risk, a new report found. The annual workforce census by the Royal College of Radiologists (RCR) warned that the safe delivery of NHS cancer care is becoming 'increasingly impossible' due to an escalating shortfall of doctors coupled with rising demand for care. In 2024, the UK had a 29% shortfall of clinical radiologists, with regional gaps ranging from 25% in Scotland to 32% in Wales. The workforce grew by 4.7% that year — less than in 2023, when it increased by 6.3%. The college forecasts the radiologist shortfall will reach 39% by 2029. Oncology Under Strain Clinical oncologists are also in short supply, with a current 15% gap expected to rise to 19% by 2029. This is despite a 5.4% increase in the workforce in 2024—the strongest growth since 2018. The RCR reported that 23% of cancer centres were experiencing recruitment freezes, making it harder to meet growing demand. Demand Continues to Outpace Capacity The shortages threaten the government's plans to cut waiting times and improve cancer outcomes. In 2024, demand for computerised tomography (CT) and magnetic resonance imaging (MRI) grew by 8%, but workforce growth did not keep pace. Every radiology leader surveyed last year reported delays to diagnostic scans caused by staff shortages. Nine in 10 radiology team leaders reported that patients were waiting longer to start treatment, while seven in 10 expressed concern that staff shortages were putting patient safety at risk – down slightly from 85% in 2023. Chronic problems such as workforce shortages, reporting backlogs, and staff vacancies remain too high, according to Dr Robin Proctor, the RCR's m edical director responsible for professional practice and clinical radiology. Consultants Leaving Earlier Staff retention is worsening, with experienced consultants leaving the NHS at younger ages. In 2024, the median age of consultant clinical radiologists leaving the NHS workforce was 50 – down from 56 in 2020. Four in five (79%) of leavers were under 60, and two in five (42%) were under 45. Clinical oncologists followed a similar trend. Their median exit age dropped to 54, from 57 in 2023 and 59 in 2022. Nearly 76% of leavers were under 60, and 26% were under 45. One consultant clinical oncologist told the college that delays in scans and treatment were resulting in missed or late cancer diagnoses. Some patients' conditions were deteriorating or reaching a stage where treatment was no longer possible. Changing Work Practices 'Working conditions and ways of working need to change if we are to address this problem and meet the growing demand for our expertise,' Proctor said. The RCR has called on the government to invest in training and recruitment. In 2024, the NHS spent an estimated £325 million on temporary radiology staff. The cost of outsourcing had doubled since before the COVID-19 pandemic and had surged by almost a quarter in the past year. The RCR estimated that increasing radiology trainee numbers by 50% could eliminate three-quarters of the current shortfall and save the NHS £460 million over the next 10 years. 'Patients are being failed by a chronic lack of radiologists and oncologists,' said RCR president Dr Katharine Halliday. 'The longer we delay action, the worse it gets,' she added.
Yahoo
16 hours ago
- Yahoo
WVU Medicine Princeton Community Hospital breaks ground on PCH Bluefield campus
BLUEFIELD, WV (WVNS) – WVU Medicine continues to expand with the breaking of ground for the new Bluefield campus of Princeton Community Hospital. Located on Southview Drive, the $25 million facility will offer state-of-the-art care to residents in the area. The location will be home to the Bluefield Emergency Department and PCH Behavioral Health Center, and the expansion itself is part of an effort by WVU Medicine to offer comprehensive access and care to patients no matter where they are in the state, according to Princeton Community Hospital President and CEO, Karen Bowling.'One reason WVU Medicine has expanded is we want to make sure we are serving the entire community and that it is a comprehensive level of care,' she said. 'If you think about it, we're on the same medical record. Whether you're in Princeton or you're in Bluefield, whether you need to go to Ruby to have a bone marrow transplant – we're all on the same medical record.'Bowling said the expansion is about communities, families, and serving the region as well as the state. 'As someone who grew up in this region, I know firsthand how much this investment means,' she continued. 'This project is about more than bricks and mortar; it's about giving our families, friends, and neighbors access to the kind of care they deserve, right here at home. WVU Medicine is making a promise to this region, and I'm proud to be part of delivering on that promise.' WVU Medicine President & CEO, Albert Wright reiterated the importance of widespread coverage under a single umbrella as it pertains to patient care. 'This project exemplifies WVU Medicine's unwavering investment in delivering high-quality, accessible care to West Virginians,' he said. 'By expanding services and upgrading facilities, like here at the Bluefield Campus, we're not only enhancing patient care, but we're also reinforcing our long-term commitment to advancing health outcomes in southern West Virginia.'Features of the Bluefield campus will include: The new emergency department (ED) will include: 20 exam rooms, including two rooms designed for psychiatric intake Two resuscitation rooms and two triage rooms OB-ready and trauma rooms Centralized care team support stations Dedicated patient and ambulance entrances Diagnostic Radiology — two radiology rooms Computed Tomography (CT) — one CT scanner Magnetic Resonance Imaging (MRI) — one MRI scanner (a new service for Bluefield) Ultrasound — two ultrasound rooms (a new service for Bluefield) Guest speakers and live music were part of the groundbreaking celebration as guests got their first look at plans for the new facility. PCH plans to officially open the doors to its Bluefield campus in the Fall of 2027, as the provider hopes to further extend the scope of patient accessibility and care. Copyright 2025 Nexstar Media, Inc. All rights reserved. This material may not be published, broadcast, rewritten, or redistributed.